Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Dexlansoprazole from Oranienburg vs Osaka Plants
NCT03801148Phase 1Completed
- Sponsor
- Takeda
- Start
- Jan 2019
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dexlansoprazole in gastroesophageal reflux disease (GERD) (4 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration for Dexlansoprazole at Day 1, Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration at Day 1 and 1 more. Started Jan 2019; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03801148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03801148.